Abstract
IntroductionThe lack of definitive means to prevent or treat cognitive impairment or dementia is driving intense efforts to identify causal mechanisms. Recent evidence suggests clinically meaningful declines in cognition might present as early as middle age. Studying cognitive changes in middle adulthood could elucidate modifiable factors affecting later cognitive and health outcomes, yet few cognitive ageing studies include this age group. The purpose of the MidCog study is to begin investigations of less-studied and potentially modifiable midlife determinants of later life cognitive outcomes.Methods and analysisMidCog is a prospective cohort study of adults ages 35–64, with two in-person interviews 2.5 years apart. Data will be collected from interviews, electronic health records and pharmacy fill data. Measurements will include health literacy, self-management skills, cognitive function, lifestyle and health behaviours, healthcare use, health status and chronic disease outcomes. Associations of health literacy and self-management skills with health behaviours and cognitive/health outcomes will be examined in a series of regression models, and moderating effects of modifiable psychosocial factors.Finally, MidCog data will be linked to an ongoing, parallel cohort study of older adults recruited at ages 55–74 in 2008 (‘LitCog’; ages 70–90 in 2023), to explore associations between age, health literacy, self-management skills, chronic diseases, health status and cognitive function among adults ages 35–90.Ethics and disseminationThe Institutional Review Board at Northwestern University has approved the MidCog study protocol (STU00214736). Results will be published in peer-reviewed journals and summaries will be provided to the funders of the study as well as patients.
Funder
National Institute on Aging
National Center for Advancing Translational Sciences
Reference101 articles.
1. United Nations Department of Economic and Social Affairs PD . World population aging 2019 highlights; 2019.
2. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
3. Aducanumab: first approval;Dhillon;Drugs,2021
4. Recent progress in Alzheimer’s disease research, part 3: diagnosis and treatment;Hane;J Alzheimers Dis,2017
5. U.S. Food and Drug Administration . FDA grants accelerated approval for alzheimer’s disease treatment. Available: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment [Accessed 10 Jan 2023].
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献